您好,欢迎来到试剂信息网! [登录] [免费注册]
试剂信息网
位置:首页 > 产品库 > MYF-01-37
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
MYF-01-37
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
MYF-01-37图片
规格:98%
分子量:298.3
包装与价格:
包装价格(元)
5mg电议
10mg电议
50mg电议
100mg电议

产品介绍
MYF-01-37 是一种共价 TEAD 抑制剂,靶向 Cys380。MYF-01-37 可逆地抑制 YAP/TEAD 相互作用。
货号:ajcx34996
CAS:2416417-65-5
分子式:C15H17F3N2O
分子量:298.3
溶解度:DMSO : 250 mg/mL (838.08 mM; Need ultrasonic)
纯度:98%
存储:Store at -20°C
库存:现货

Background:

MYF-01-37 is a covalent TEAD inhibitor targeting Cys380. MYF-01-37 has a reversible inhibition on YAP/TEAD interaction[1].

MYF-01-37 (10 μM; 24h) results in inhibition of direct YAP/TEAD interaction in HEK 293T cells, and in the reduction in canonical YAP target gene CTGF expression in PC-9 cells[1]. MYF-01-37 (0.1, 1, 10, 100 μM) has minimal impact on cell viability of several EGFR-mutant NCSLC cell lines[1]. MYF-01-37 (10 μM; 10 days) combinated with OT (combination of osimertinib and trametinib) leads to a dramatic decrease in dormant cells compared to OT alone[1].

[1]. Kari J Kurppa, et al. Treatment-Induced Tumor Dormancy through YAP-Mediated Transcriptional Reprogramming of the Apoptotic Pathway. Cancer Cell. 2020 Jan 13;37(1):104-122.e12.